

# Ivan Gentile

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4885038/publications.pdf](https://exaly.com/author-pdf/4885038/publications.pdf)

Version: 2025-02-01

176  
papers

3,736  
citations

139253

30  
h-index

202090

46  
g-index

218  
all docs

218  
docs citations

218  
times ranked

6723  
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized care approaches to hepatitis C therapy: recent advances and future directions. Expert Review of Anti-Infective Therapy, 2024, 22, 139-151.	4.1	0
2	Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program. Microorganisms, 2024, 12, 903.	4.0	1
3	Role of Cefiderocol in Multidrug-Resistant Gram-Negative Central Nervous System Infections: Real Life Experience and State-of-the-Art. Antibiotics, 2024, 13, 453.	4.2	1
4	Immune Profile in COVID-19: Unveiling TR3-56 Cells in SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2024, 25, 10465.	4.5	0
5	Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study. Antibiotics, 2024, 13, 1007.	4.2	0
6	Urinary Tract Infections in Kidney Transplant Patients: An Open Challenge”Update on Epidemiology, Risk Factors and Management. Microorganisms, 2024, 12, 2217.	4.0	0
7	Invasive Fungal Infections in Hospitalized Patients with COVID-19: A Non-Intensive Care Single-Centre Experience during the First Pandemic Waves. Journal of Fungi (Basel, Switzerland), 2023, 9, 86.	3.6	10
8	Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study. Vaccines, 2023, 11, 200.	3.1	7
9	The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel. Diagnostics, 2023, 13, 320.	3.3	11
10	Diabetes and SARS-CoV-2 Infection: The Potential Role of Antidiabetic Therapy in the Evolution of COVID-19. Microorganisms, 2023, 11, 145.	4.0	1
11	CEFTO-CURE study: CEFTObiprole Clinical Use in Real-life “ a multi-centre experience in Italy. International Journal of Antimicrobial Agents, 2023, 62, 106817.	4.1	13
12	COVID-19: Where We Are and Where We Are Going. Diseases (Basel, Switzerland), 2023, 11, 40.	2.8	2
13	Stenotrophomonas maltophilia Infections: A Systematic Review and Meta-Analysis of Comparative Efficacy of Available Treatments, with Critical Assessment of Novel Therapeutic Options. Antibiotics, 2023, 12, 910.	4.2	12
14	Obesity as a Risk Factor of Severe Outcome of COVID-19: A Pair-Matched 1:2 Case”Control Study. Journal of Clinical Medicine, 2023, 12, 4055.	2.6	13
15	Prevalence and Epidemiological and Clinical Features of Bacterial Infections in a Large Cohort of Patients Hospitalized for COVID-19 in Southern Italy: A Multicenter Study. Antibiotics, 2023, 12, 1124.	4.2	0
16	Prognostic Value of Creatinine Levels at Admission on Disease Progression and Mortality in Patients with COVID-19”An Observational Retrospective Study. Pathogens, 2023, 12, 973.	3.1	4
17	Risk Factors for Pneumocystis jirovecii Pneumonia in Non-HIV Patients Hospitalized for COVID-19: A Case-Control Study. Journal of Fungi (Basel, Switzerland), 2023, 9, 838.	3.6	1
18	Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. Antibiotics, 2022, 11, 183.	4.2	19

#	ARTICLE	IF	CITATIONS
19	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	11.6	20
20	COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination. <i>PLoS Medicine</i> , 2022, 19, e1003917.	8.1	20
21	Loss of Detection of sgN Precedes Viral Abridged Replication in COVID-19-Affected Patients—A Target for SARS-CoV-2 Propagation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1941.	4.5	6
22	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. <i>Journal of Neurology</i> , 2022, 269, 3301-3307.	3.4	14
23	Reliability of fr-AGILE tool to evaluate multidimensional frailty in hospital settings for older adults with COVID-19. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 939-944.	2.9	3
24	Inducible Nitric Oxide Synthase (iNOS): Why a Different Production in COVID-19 Patients of the Two Waves?. <i>Viruses</i> , 2022, 14, 534.	3.3	14
25	Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19. <i>Minerva Endocrinology</i> , 2022, 47, .	1.2	10
26	Sotrovimab in Solid Organ Transplant Patients With Early, Mild/Moderate SARS-CoV-2 Infection: A Single-center Experience. <i>Transplantation</i> , 2022, 106, e343-e345.	1.0	18
27	Diabetes and COVID-19: The potential role of mTOR. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109813.	4.8	17
28	SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience. <i>Frontiers in Medicine</i> , 2022, 9, .	2.7	9
29	A Phase II Study on the Effect of Taurisolo <sup>®</sup> Administered via AEROSol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study. <i>Cells</i> , 2022, 11, 1499.	4.8	9
30	Should SARS CoV-2 Infection be Considered an Independent Risk Factor for <i>Pneumocystis jirovecii</i> Pneumonia? Emerging Data after Two Years of Pandemic from a Single Center Experience. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 220-222.	1.0	1
31	Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals. <i>Genetics in Medicine</i> , 2022, 24, 1653-1663.	2.3	8
32	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103814.	2.1	2
33	Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19—An Observational Retrospective Study. <i>Pathogens</i> , 2022, 11, 652.	3.1	11
34	Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection. <i>Journal of Clinical Medicine</i> , 2022, 11, 4306.	2.6	7
35	Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients. <i>Viruses</i> , 2022, 14, 1951.	3.3	2
36	Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion. <i>Antibiotics</i> , 2022, 11, 1263.	4.2	19

#	ARTICLE	IF	CITATIONS
37	Calprotectin Levels and Neutrophil Count Are Prognostic Markers of Mortality in COVID-19 Patients. <i>Diagnostics</i> , 2022, 12, 2554.	3.3	8
38	Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. <i>Vaccines</i> , 2022, 10, 1731.	3.1	48
39	Trends in Caesarean Section Rate According to Robson Group Classification among Pregnant Women with SARS-CoV-2 Infection: A Single-Center Large Cohort Study in Italy. <i>Journal of Clinical Medicine</i> , 2022, 11, 6503.	2.6	5
40	Update on the Management of Surgical Site Infections. <i>Antibiotics</i> , 2022, 11, 1608.	4.2	13
41	Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge. <i>Vaccines</i> , 2022, 10, 1895.	3.1	3
42	A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19. <i>Vaccines</i> , 2022, 10, 2043.	3.1	0
43	Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issuesâ€”A Delphi Consensus Project. <i>Journal of Clinical Medicine</i> , 2022, 11, 6946.	2.6	1
44	Clinical Characterization of the Three Waves of COVID-19 Occurring in Southern Italy: Results of a Multicenter Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16003.	3.1	8
45	Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre caseâ€“controlâ€“control study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 276-282.	5.5	29
46	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	4.4	88
47	Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2078.	3.1	25
48	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitely Get a Role to Fusobacterium periodonticum?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, .	4.2	57
49	Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, .	3.7	116
50	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. <i>Journal of Clinical Medicine</i> , 2021, 10, 1127.	2.6	12
51	<i>Pneumocystis jirovecii</i> pneumonia in an immunocompetent patient recovered from COVID-19. <i>Infectious Diseases</i> , 2021, 53, 382-385.	1.8	22
52	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life â€“Liver Network Activityâ€™ (LINA) cohort update results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1057-1063.	2.4	2
53	Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy. <i>Life</i> , 2021, 11, 347.	2.8	2
54	Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19. <i>IScience</i> , 2021, 24, 102322.	3.8	61

#	ARTICLE	IF	CITATIONS
55	Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 925-936.	2.8	13
56	Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e77-e78.	4.1	12
57	Chest CT in COVID-19 patients: Structured vs conventional reporting. <i>European Journal of Radiology</i> , 2021, 138, 109621.	3.1	12
58	B-Type Natriuretic Peptides and High-Sensitive Troponin I as COVID-19 Survival Factors: Which One Is the Best Performer?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2726.	2.6	9
59	The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy. <i>Genes</i> , 2021, 12, 881.	2.7	15
60	Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?. <i>Frontiers in Public Health</i> , 2021, 9, .	2.9	22
61	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. <i>Frontiers in Medicine</i> , 2021, 8, .	2.7	20
62	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	2.4	3
63	Gastrointestinal tract diseases as a risk factor for SARS-CoV2 rectal shedding? An Italian report on 10 COVID-19 patients. <i>Intestinal Research</i> , 2021, 19, 354-356.	3.0	3
64	Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, .	2.7	1
65	Daptomycin versus Vancomycin for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infection with or without Endocarditis: A Systematic Review and Meta-Analysis. <i>Antibiotics</i> , 2021, 10, 1014.	4.2	34
66	A Transient Increase in the Serum ANCAs in Patients with SARS-CoV-2 Infection: A Signal of Subclinical Vasculitis or an Epiphenomenon with No Clinical Manifestations? A Pilot Study. <i>Viruses</i> , 2021, 13, 1718.	3.3	12
67	Further Findings Concerning Endothelial Damage in COVID-19 Patients. <i>Biomolecules</i> , 2021, 11, 1368.	4.4	10
68	The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9548.	4.5	61
69	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11159.	3.1	11
70	Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4914.	2.6	14
71	<i>Pneumocystis jirovecii</i> Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11399.	3.1	27
72	<i>Pneumocystis jirovecii</i> pneumonia in COVID-19: an overlooked clinical entity? Response to <i>Pneumocystis pneumonia</i> risk among viral acute respiratory distress syndrome related or not to COVID 19? <i>Critical Care</i> , 2021, 25, .	6.9	2

#	ARTICLE	IF	CITATIONS
73	Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 123-126.	4.1	22
74	Ceftolozane/tazobactam for difficult-to-treat <i>Pseudomonas aeruginosa</i> infections: A systematic review of its efficacy and safety for off-label indications. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105891.	4.1	36
75	Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 261-273.	2.3	7
76	Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. <i>Infectious Diseases</i> , 2020, 52, 216-218.	1.8	4
77	Current trends in the real-life use of dalbavancin: report of a study panel. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106107.	4.1	23
78	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	3.4	132
79	Prohibitin 2 is Involved in Parkin-Mediated Mitophagy in Urothelial Cells of Cattle Infected with Bovine Papillomavirus. <i>Pathogens</i> , 2020, 9, 621.	3.1	10
80	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Caseâ€“Control Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, .	0.8	8
81	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. <i>Journal of Clinical Medicine</i> , 2020, 9, 4066.	2.6	18
82	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. <i>Life Sciences</i> , 2020, 261, 118355.	4.5	32
83	COVID-19: Time for Post-Exposure Prophylaxis?. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3997.	3.1	9
84	COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102282.	2.1	9
85	SARS-CoV-2 and liver damage: a possible pathogenetic link. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 322-324.	1.6	7
86	COVID-19: Perspectives on the Potential Novel Global Threat. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 84-86.	1.0	22
87	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. <i>Medicine (United States)</i> , 2020, 99, e18948.	1.3	7
88	Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR <i>Pseudomonas aeruginosa</i> in patients with impaired renal function: a case series from a single-center experience. <i>Infection</i> , 2020, 48, 303-307.	3.0	4
89	Changes in the relative prevalence of candidaemia due to nonâ€“ <i>albicans Candida</i> species in adult inâ€“patients: A systematic review, metaâ€“analysis and metaâ€“regression. <i>Mycoses</i> , 2020, 63, 334-342.	3.3	45
90	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.5	10

#	ARTICLE	IF	CITATIONS
91	Epidemiology of Coronavirus Disease Outbreak: The Italian Trends. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 87-92.	1.0	23
92	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 191-202.	4.1	3
93	No Detection of SARS-CoV-2 RNA on Urethral Swab in Patients with Positive Nasopharyngeal Swab. <i>Advances in Virology</i> , 2020, 2020, 1-4.	1.1	4
94	The role of curcumin in liver diseases. <i>Archives of Medical Science</i> , 2019, 15, 1608-1620.	1.2	21
95	Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease. <i>IDCases</i> , 2019, 17, e00537.	0.9	8
96	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	4.2	29
97	Patients with HCV Genotype-1 who have Failed a Direct-Acting Antiviral Regimen: Virological Characteristics and Efficacy of Retreatment. <i>Antiviral Therapy</i> , 2019, 24, 485-493.	2.1	5
98	Meet Our Editorial Board Member. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 1-2.	1.0	0
99	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. <i>Journal of Nephrology</i> , 2019, 32, 763-773.	1.6	23
100	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.8	19
101	Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 663-673.	3.5	41
102	Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. <i>In Vivo</i> , 2019, 33, 177-182.	1.3	17
103	The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e57-e60.	1.8	5
104	Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. <i>Internal and Emergency Medicine</i> , 2019, 15, 263-271.	2.5	23
105	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 129-135.	1.0	5
106	Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 173-182.	1.0	30
107	NS5B polymerase inhibitors in phase II clinical trials for HCV infection. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 243-250.	4.1	9
108	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	3.8	14

#	ARTICLE	IF	CITATIONS
109	Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 329-336.	1.4	30
110	Response to: "Letter to the Editor: "Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the Intensive Care Unit: state of the art"™. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 369-371.	4.1	1
111	Meet Our Editorial Board Member. <i>Reviews on Recent Clinical Trials</i> , 2018, 13, 83-83.	1.0	0
112	Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders. <i>In Vivo</i> , 2018, 32, 1255-1258.	1.3	3
113	Current evidence on the management of hepatitis B in pregnancy. <i>World Journal of Hepatology</i> , 2018, 10, 585-594.	2.3	5
114	Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 709-717.	2.8	50
115	Liver fungal infections: an overview of the etiology and epidemiology in patients affected or not affected by oncohematologic malignancies. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 177-186.	2.6	23
116	Current and emerging pharmacotherapy for the treatment of bacterial peritonitis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1317-1325.	2.3	8
117	Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity "LINA) Tj ETQq1 1 0.784344rgBT /Overlock		
118	Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1800-1802.	6.4	16
119	Hepatitis B mother-to-child transmission and infants immunization: we have not come to the end of the story yet. <i>Infectious Diseases</i> , 2017, 49, 584-587.	1.8	3
120	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. <i>Antiviral Therapy</i> , 2017, 22, 551-558.	2.1	12
121	No Evidence of Congenital Varicella Zoster Virus Infection Assessed Through Dried Blood Spot in Children With Autism Spectrum Disorders. <i>Future Virology</i> , 2017, 12, 333-337.	1.3	1
122	Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. <i>European Journal of Internal Medicine</i> , 2017, 46, e45-e47.	2.6	14
123	Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the intensive care unit: state of the art. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 861-871.	4.1	48
124	Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. <i>International Journal of Infectious Diseases</i> , 2017, 63, 23-29.	2.2	25
125	Successful treatment of post-surgical osteomyelitis caused by XDR <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2678-2679.	3.2	15
126	Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1409-1414.	2.1	17

#	ARTICLE	IF	CITATIONS
127	Current concepts and future strategies in the antimicrobial therapy of emerging Gram-positive spontaneous bacterial peritonitis. <i>World Journal of Hepatology</i> , 2017, 9, 1166-1175.	2.3	42
128	Direct acting antiviral agents and hepatocellular carcinoma development: don't take it for granted. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 101-101.	2.2	4
129	Is Anticoagulation with Novel Oral Anticoagulants an Effective Treatment for Tuberculosis Patients not Achieving a Therapeutic Range with Vitamin K Antagonists? A Systematic Review. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2017, 17, .	0.6	6
130	Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders. <i>In Vivo</i> , 2017, 31, 467-473.	1.3	18
131	What is the role of the new $\beta$ -lactam/ $\beta$ -lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 875-878.	4.1	17
132	The therapeutic potential of new investigational hepatitis C virus translation inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1209-1214.	4.1	13
133	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1364-1369.	1.3	10
134	Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1227-1234.	2.4	16
135	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 557-572.	4.1	18
136	Lack of evidence that adherence to standard of care therapy improves survival in subjects with hepatocellular carcinoma in clinical practice. <i>Journal of Medical Virology</i> , 2015, 87, 1368-1376.	3.8	2
137	Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. <i>Annals of Hepatology</i> , 2015, 14, 75-82.	1.3	42
138	Fecal microbiota transplantation for <i>Clostridium difficile</i> infection: back to the future. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1001-1014.	3.2	15
139	A pill a day keeps HCV away. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 616-617.	15.7	8
140	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. <i>Therapeutics and Clinical Risk Management</i> , 2014, , 493.	2.1	24
141	Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. <i>Reviews on Recent Clinical Trials</i> , 2014, 9, 1-7.	1.0	22
142	Vertical transmission of hepatitis B virus: challenges and solutions. <i>International Journal of Women's Health</i> , 2014, , 605.	2.3	66
143	Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 20-26.	1.3	20
144	Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 763-773.	4.1	27

#	ARTICLE	IF	CITATIONS
145	Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1211-1223.	4.1	20
146	Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 775-782.	4.1	25
147	Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment. <i>Evidence-Based Medicine</i> , 2014, 19, 223-224.	0.7	4
148	ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. <i>Current Medicinal Chemistry</i> , 2014, 21, 3261-3270.	2.5	33
149	Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection. <i>Reviews on Recent Clinical Trials</i> , 2014, 9, 115-123.	1.0	41
150	Antibiotic prophylaxis and risk of infections in thyroid surgery: results from a national study (UECâ€™Italian Endocrine Surgery Units Association). <i>Updates in Surgery</i> , 2013, 65, 213-216.	1.8	23
151	Movement disorders as presenting symptoms of AIDS. <i>Basal Ganglia</i> , 2013, 3, 175-178.	0.5	2
152	Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2533-2544.	2.3	16
153	Etiopathogenesis of autism spectrum disorders: Fitting the pieces of the puzzle together. <i>Medical Hypotheses</i> , 2013, 81, 26-35.	0.7	37
154	Resolution of autoimmune thrombocytopenia associated with raltegravir use in an HIV-positive patient. <i>Platelets</i> , 2013, 24, 574-577.	2.5	11
155	A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C. <i>Hepatitis Monthly</i> , 2013, 13, .	0.5	14
156	Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 33, 559-567.	2.4	20
157	Sustained virological response: A milestone in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2013, 19, 2793.	4.7	47
158	Hepatitis B in pregnancy. <i>World Journal of Gastroenterology</i> , 2012, 18, 4677.	4.7	167
159	Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review. <i>BMC Infectious Diseases</i> , 2010, 10, .	2.7	55
160	Noninvasive prediction of oesophageal varices: as simple as blood count?. <i>Liver International</i> , 2010, 30, 1091-1093.	4.2	3
161	Development and progression of gastroesophageal varices in patients with chronic hepatitis C. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 867-870.	4.1	0
162	Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. <i>Journal of Hepatology</i> , 2010, 52, 778.	2.9	10

#	ARTICLE	IF	CITATIONS
163	The efficacy and safety of telaprevir â€“ a new protease inhibitor against hepatitis C virus. Expert Opinion on Investigational Drugs, 2010, 19, 151-159.	4.1	32
164	Iron depletion before HCV antiviral therapy: A pilot, randomized, controlled trial. Journal of Clinical Apheresis, 2009, 24, 190-196.	2.6	17
165	Homocysteine levels and sustained virological response to pegylatedâ€interferon Î±2b plus ribavirin therapy for chronic hepatitis C: a prospective study. Liver International, 2009, 29, 248-252.	4.2	23
166	A Simple Noninvasive Score Predicts Gastroesophageal Varices in Patients With Chronic Viral Hepatitis. Journal of Clinical Gastroenterology, 2009, 43, 81-87.	2.5	22
167	Multiple Sclerosis and Hepatitis C Virus Infection Are Associated with Single Nucleotide Polymorphisms in Interferon Pathway Genes. Journal of Interferon and Cytokine Research, 2008, 28, 141-152.	1.8	34
168	A rare case of brainstem encephalitis by Listeria monocytogenes with isolated mesencephalic localization. Case report and review. Diagnostic Microbiology and Infectious Disease, 2007, 58, 121-123.	1.7	30
169	A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?. Acta Diabetologica, 2007, 44, 167-169.	2.3	20
170	Case Report: Hemolytic Anemia During Pegylated IFN-Î±2b Plus Ribavirin Treatment for Chronic Hepatitis C: Ribavirin Is Not Always the Culprit. Journal of Interferon and Cytokine Research, 2005, 25, 283-285.	1.8	17
171	HIV and Hepatitis C Virus: Facts and Controversies. Infection, 2003, 31, 232-240.	3.0	9
172	Case Report: Pernicious Anemia During IFN-Î± Treatment for Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2003, 23, 11-12.	1.8	16
173	Myasthenia Gravis During Low-Dose IFN-Î± Therapy for Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2001, 21, 469-470.	1.8	30
174	Multivariate Discriminant Function Based on Six Biochemical Markers in Blood Can Predict the Cirrhotic Evolution of Chronic Hepatitis. Clinical Chemistry, 2001, 47, 1696-1700.	1.1	45
175	A Case of Paracoccidioidomycosis: Experience with Long-Term Therapy. Infection, 2000, 28, 119-120.	3.0	15
176	Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak. BMJ, The, 0, , m1254.	0.2	67